Last reviewed · How we verify
IVACFLU-S
IVACFLU-S is a recombinant influenza vaccine that stimulates immune responses against seasonal influenza virus strains.
IVACFLU-S is a recombinant influenza vaccine that stimulates immune responses against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | IVACFLU-S |
|---|---|
| Sponsor | Institute of Vaccines and Medical Biologicals, Vietnam |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IVACFLU-S is a live attenuated or inactivated influenza vaccine developed using recombinant DNA technology to express viral antigens. It is designed to induce both humoral and cellular immune responses to protect against seasonal influenza infection. The vaccine targets multiple influenza virus strains included in its formulation to provide broad seasonal coverage.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam (PHASE3)
- Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3 (PHASE2, PHASE3)
- Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |